DRMAW
Dermata Therapeutics Inc. WarrantNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
$-2.16
Beta
0.67
52W High
$0.03
52W Low
$0.01
50-Day MA
$0.00
200-Day MA
$0.00
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Dermata Therapeutics Inc. Warrant
Dermata Therapeutics Inc. is an innovative biotechnology firm dedicated to developing advanced therapies for dermatological diseases, particularly those with significant unmet medical needs, such as acne. Leveraging its proprietary platform, the company is making strides in creating innovative treatments that address a growing prevalence of skin disorders. With a diverse pipeline of product candidates, Dermata is strategically positioned for growth in the burgeoning biotech market, making it an attractive option for institutional investors seeking impactful and transformative healthcare solutions.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-4.09M |
| Operating Margin | 0.00% |
| Return on Equity | -194.20% |
| Return on Assets | -85.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.34 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | $3.17M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
HV 10-Day
97.83%
HV 20-Day
104.95%
HV 30-Day
180.05%
HV 60-Day
159.13%
HV Rank
—
Volatility is currently contracting
Data last updated: 5/5/2026